| Biological Sciences | 2021-2025 | 82 | CN 32 | 99.93 |
| Medical and Health Sciences | 2021-2025 | 560 | CN 59 | 99.88 |
| Cancer Research | Lifetime | 193 | CN 11 | 98.90 |
| Oncology | Lifetime | 958 | CN 35 | 97.85 |
| Molecular Medicine | Lifetime | 481 | CN 58 | 82.95 |
| Obstetrics and Gynecology | Lifetime | 938 | CN 15 | 82.57 |
| Endocrinology | Lifetime | 619 | CN 27 | 79.16 |
| Microbiology | Lifetime | 735 | CN 26 | 70.13 |
| Parasitology | Lifetime | 861 | CN 25 | 47.17 |
| Molecular Biology | 2021-2025 | 58 | CN 27 | 99.77 |
| Cancer Research | 2021-2025 | 25 | CN 10 | 99.15 |
| Immunology | 2021-2025 | 158 | CN 36 | 96.65 |
| Oncology | 2021-2025 | 310 | CN 35 | 97.09 |
| Epidemiology | 2021-2025 | 464 | CN 51 | 95.93 |
| Molecular Medicine | 2021-2025 | 57 | CN 12 | 93.77 |
| Infectious Diseases | 2021-2025 | 362 | CN 36 | 93.09 |
| Rheumatology | 2021-2025 | 274 | CN 16 | 90.98 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 736 | CN 87 | 90.70 |
| Obstetrics and Gynecology | 2021-2025 | 245 | CN 9 | 90.18 |
| Genetics | 2021-2025 | 548 | CN 43 | 84.47 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 840 | CN 103 | 79.25 |
| Complementary and Alternative Medicine | 2021-2025 | 229 | CN 48 | 67.91 |
| Cancer-related molecular mechanisms research | Lifetime | 96 | CN 33 | 99.49 |
| Circular RNAs in diseases | Lifetime | 56 | CN 26 | 99.38 |
| MicroRNA in disease regulation | Lifetime | 134 | CN 42 | 99.37 |
| Traditional Chinese Medicine and Integrative Care | Lifetime | 64 | CN 43 | 96.38 |
| Extracellular vesicles in disease | Lifetime | 178 | CN 49 | 98.17 |
| RNA modifications and cancer | Lifetime | 668 | CN 80 | 98.71 |
| Cancer-related gene regulation | Lifetime | 432 | CN 46 | 97.83 |
| Cancer Mechanisms and Therapy | Lifetime | 466 | CN 69 | 95.45 |
| Ferroptosis and cancer prognosis | Lifetime | 670 | CN 378 | 93.97 |
| Wnt/β-catenin signaling in development and cancer | Lifetime | 734 | CN 36 | 93.27 |
| Beetle Biology and Toxicology Studies | Lifetime | 616 | CN 141 | 54.06 |
| Extracellular vesicles in disease | 2021-2025 | 17 | CN 13 | 99.33 |
| Cancer-related molecular mechanisms research | 2021-2025 | 52 | CN 34 | 99.50 |
| MicroRNA in disease regulation | 2021-2025 | 73 | CN 46 | 98.78 |
| Circular RNAs in diseases | 2021-2025 | 54 | CN 39 | 98.37 |
| Cancer-related gene regulation | 2021-2025 | 68 | CN 43 | 95.12 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 264 | CN 66 | 96.68 |
| RNA modifications and cancer | 2021-2025 | 643 | CN 435 | 95.18 |
| Ferroptosis and cancer prognosis | 2021-2025 | 651 | CN 553 | 92.23 |
| Immune cells in cancer | 2021-2025 | 891 | CN 483 | 88.49 |
| Peptidase Inhibition and Analysis | 2021-2025 | 644 | CN 189 | 89.63 |
| Cancer Cells and Metastasis | 2021-2025 | 955 | CN 202 | 83.71 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 450 | CN 84 | 84.87 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 989 | CN 76 | 79.45 |
| Escherichia coli research studies | 2021-2025 | 430 | CN 62 | 76.96 |
| Enterobacteriaceae and Cronobacter Research | 2021-2025 | 247 | CN 72 | 67.07 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 580 | CN 89 | 65.25 |
| Wnt/β-catenin signaling in development and cancer | 2021-2025 | 497 | CN 130 | 58.42 |